News
Displaying 1–10 of 517
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Research NewsDr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Foundation News
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status.
-
Foundation News
Chairwoman Capito, Ranking Member Baldwin, and members of the Senate Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Foundation Fighting Blindness appreciates the opportunity to provide written testimony to the subcommittee as an outside witness.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Presentation Summaries from the 10th Annual Retinal Therapy Innovation Summit
Research NewsIn its tenth year, the Innovation Summit featured 28 presentations from industry professionals worldwide and more than 400 attendees.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Foundation News
The Foundation Fighting Blindness develops strategic partnership with Alma, a network of 25,000 mental health professionals dedicated to simplifying access to high-quality, affordable mental healthcare.
.jpg)
